FiercePharma  Jun 23  Comment 
China’s FDA joined ICH as a regulatory member, Takeda wrapped up construction of new solid dosage plant in Germany, the FDA bans imports of Ipca Lab drugs.
The Hindu Business Line  Jun 21  Comment 
Alembic Pharmaceuticals has received the US health regulator’s approval to market hypertension drug Candesartan Cilexetil tablets in the US. The company’s product is therapeutically equivalent to As...
GenEng News  Jun 12  Comment 
Computational drug design company Numerate said today it will use its artificial intelligence (AI) platform to identify and deliver multiple clinical candidates for Takeda Pharmaceutical Company, through a collaboration whose value was not...
FiercePharma  Jun 6  Comment 
CEO Christophe Weber has projected that new oral multiple myeloma drug Ninlaro, a first-to-market active proteasome inhibitor, is on course to be Takeda's best-selling cancer drug. To stay ahead of that success, the Japanese drugmaker is starting...
FiercePharma  Jun 5  Comment 
Which pharma company has the best reputation? Boston-based Reputation Institute has a few ideas. A study based on more than 16,500 reputation ratings collected throughout the U.S., Europe and Brazil during the first two months of this year has...
FiercePharma  Jun 5  Comment 
Takeda’s cancer unit debuted a new face at this year’s American Society of Clinical Oncology annual meeting—and the company was quick to bill it as such.
FiercePharma  May 25  Comment 
Nonprofit executive Ethan Brewster can suddenly create body doubles of himself, while nurse Jiang Goh’s new superpower allows her to instantly heal injuries. If it sounds like a Marvel superhero comic plot, that’s because it is.
FierceBiotech  May 24  Comment 
OrphoMed gained a $39 million early funding boost from a Japanese big pharma and a host of VCs as it looks to push on with work on its leading med for forms of irritable bowel syndrome that it hopes can have a better safety profile than those meds...
FierceBiotech  May 22  Comment 
Perennial biotech investor and backer Takeda has signed its latest collaboration with Nektar Therapeutics that will see the pair work on combo cancer approaches with NKTR-214, a CD122-biased agonist, as well as five Takeda oncology compounds.


No more s***. All posts of this qaultiy from now on

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki